Back to Search
Start Over
CRISPR-Cas9 applications in T cells and adoptive T cell therapies.
- Source :
-
Cellular & molecular biology letters [Cell Mol Biol Lett] 2024 Apr 12; Vol. 29 (1), pp. 52. Date of Electronic Publication: 2024 Apr 12. - Publication Year :
- 2024
-
Abstract
- T cell immunity is central to contemporary cancer and autoimmune therapies, encompassing immune checkpoint blockade and adoptive T cell therapies. Their diverse characteristics can be reprogrammed by different immune challenges dependent on antigen stimulation levels, metabolic conditions, and the degree of inflammation. T cell-based therapeutic strategies are gaining widespread adoption in oncology and treating inflammatory conditions. Emerging researches reveal that clustered regularly interspaced palindromic repeats-associated protein 9 (CRISPR-Cas9) genome editing has enabled T cells to be more adaptable to specific microenvironments, opening the door to advanced T cell therapies in preclinical and clinical trials. CRISPR-Cas9 can edit both primary T cells and engineered T cells, including CAR-T and TCR-T, in vivo and in vitro to regulate T cell differentiation and activation states. This review first provides a comprehensive summary of the role of CRISPR-Cas9 in T cells and its applications in preclinical and clinical studies for T cell-based therapies. We also explore the application of CRISPR screen high-throughput technology in editing T cells and anticipate the current limitations of CRISPR-Cas9, including off-target effects and delivery challenges, and envisioned improvements in related technologies for disease screening, diagnosis, and treatment.<br /> (© 2024. The Author(s).)
Details
- Language :
- English
- ISSN :
- 1689-1392
- Volume :
- 29
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Cellular & molecular biology letters
- Publication Type :
- Academic Journal
- Accession number :
- 38609863
- Full Text :
- https://doi.org/10.1186/s11658-024-00561-1